심부전 환자에서 엠파글리플로진의 유효성 및 안전성 검토

• Published in: Yaghag-hoi-ji Vol. 66; no. 4; pp. 175 - 183
• Main Authors: 이하늘(Ha Neul Lee), 강민구(Minku Kang), 박태은(Tae Eun Park)
• Format: Journal Article
• Language: Korean
• Published: The Pharmaceutical Society Of Korea 30.08.2022; 대한약학회
• Subjects: 약학; Heart failure; Sodium-glucose transporter 2 inhibitors; Empagliflozin
• ISSN: 0377-9556; 2383-9457
• DOI: 10.17480/psk.2022.66.4.175

The United States (US) Food and Drug Administration (FDA) approved empagliflozin, which is a sodiumglucosecotransporter 2 (SGLT2) inhibitor used for type 2 diabetes, for the treatment of heart failure (HF) with reducedejection fraction (HFrEF) in 2021. Earlier this year, empagliflozin became the only SGLT2 inhibitor approved for thetreatment of HF with preserved ejection fraction (HFpEF) as well. These approvals were based on the studies that showedempagliflozin reducing hospitalization for HF and cardiovascular mortality. Based on these new findings, SGLT2 inhibitors,including empagliflozin, have been recently added to the heart failure treatment guidelines in the US and Europe. Althoughempagliflozin is approved for adults with HFrEF in South Korea, treatment guidelines for chronic heart failure have notbeen updated to include this drug and other SGLT2 inhibitors, yet. Therefore, the purpose of this review is to examinethe studies on the efficacy and safety of empagliflozin in heart failure and its current place in clinical practice. KCI Citation Count: 0